KRYS+139.54%14.3%
NTLA-3.52%14.3%
QURE+227.95%14.3%
RARE-11.12%14.3%
SLNO0.00%14.3%
SRPT-2.03%14.3%
SRRK+38.29%14.3%
As of Aug 6, 2026, 4:25 AM ET
Rare Diseases '25: Gene Therapy & Genetic Med Constituents
Intellia Therapeutics, Inc.NTLA | 14.3% | -3.09% | 2.24% | -38.51% | 2.72% | 22.02% | -20.39% | 50.27% | -3.52% | $1.23B |
Krystal Biotech, Inc.KRYS | 14.3% | 0.31% | -2.81% | -13.05% | -4.50% | 32.14% | 18.19% | 79.99% | 139.54% | $9.60B |
Sarepta Therapeutics, Inc.SRPT | 14.3% | -2.81% | 1.59% | -16.94% | 7.20% | -25.98% | -4.95% | -74.50% | -2.03% | $1.68B |
Scholar Rock Holding CorporationSRRK | 14.3% | 0.17% | 0.42% | -13.53% | 1.22% | 8.67% | 8.13% | 47.11% | 38.29% | $5.74B |
Soleno Therapeutics, Inc.SLNO | 14.3% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | $1.06B |
Ultragenyx Pharmaceutical Inc.RARE | 14.3% | -3.41% | -7.32% | -26.02% | 0.08% | 8.39% | 6.58% | -29.52% | -11.12% | $2.46B |
uniQure N.V.QURE | 14.3% | 1.28% | 13.52% | 6.96% | 1.40% | 84.87% | 183.05% | 316.57% | 227.95% | $3.07B |
| Theme return | — | -1.08% | 1.09% | -14.46% | 1.66% | 25.00% | 23.37% | 41.35% | 47.82% | — |
| Average | 14.3% | -1.08% | 1.09% | -14.44% | 1.16% | 18.59% | 27.23% | 55.70% | 55.59% | $3.55B |
| Median | 14.3% | 0.00% | 0.42% | -13.53% | 1.22% | 8.67% | 6.58% | 47.11% | 0.00% | $2.46B |
| Std Dev | 0.0% | 1.80% | 5.90% | 14.09% | 3.24% | 31.90% | 64.58% | 117.15% | 85.70% | $2.88B |
| Min | 14.3% | -3.41% | -7.32% | -38.51% | -4.50% | -25.98% | -20.39% | -74.50% | -11.12% | $1.06B |
| Max | 14.3% | 1.28% | 13.52% | 6.96% | 7.20% | 84.87% | 183.05% | 316.57% | 227.95% | $9.60B |
| % Positive Tickers | 42.86% | 57.14% | 14.29% | 71.43% | 71.43% | 57.14% | 57.14% | 42.86% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondary
About this theme
Rare Diseases '25: Gene Therapy & Genetic Med tracks 7 publicly listed stocks in this theme: KRYS, NTLA, QURE, RARE, SLNO, SRPT, SRRK. See the constituent table for details.